AddLife is starting 2026 with continued high margins. After a strong finish to 2025, sales were somewhat subdued at the beginning of the year, but the quarter ended with good growth and the underlying trends are clearly positive. With a strong balance sheet, the pace of acquisitions has increased and two acquisitions were completed in March and April.
We strive to improve people's lives
Interim Report Q1 2026
2645
NET SALES, SEKm
332
EBITA, SEKm
12.5
%
EBITA MARGIN
61
%
P/WC
A leading partner in Life Science
AddLife is a leading independent European partner with a diversified portfolio in Life Science. AddLife owns, develops and acquires market-leading companies in specific segments with offerings aimed primarily at the healthcare sector – from research to medical care. The Group has a rooted, entrepreneur-driven culture with strong values, where sustainability is integrated into the business.
30
COUNTRIES
2300
EMPLOYEES
54000
CUSTOMERS
3500
SUPPLIERS
Labtech
The Labtech business area offers products, solutions and services in, among other things, diagnostics, biomedical research and laboratory analysis. The business area consists of two business units, Biomedical & Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies, mainly in the Nordic region and, to an increasing extent, the rest of Europe.
Medtech
Within the Medtech business area, the subsidiaries offer products and services in medical technology, as well as assistive devices and digital solutions for home care. The offering is primarily aimed at publicly funded healthcare, home care and social care in Europe, with strong positions in markets such as the UK, Ireland, the Nordic region and Spain.
Acquisitions drives long-term and profitable growth
Acquisitions are an important part of AddLife’s growth strategy and we have a well‑established and structured process to identify, acquire, integrate and develop companies. In 2025 AddLife completed three acquisitions. The acquisitions strengthen the Group’s position in prioritised growth segments and geographies and are in line with AddLife’s acquisition strategy.
BioSpectrum
CoaChrom
BioSpectrum
In March all shares in BioSpectrum Ltd., United Kingdom, were acquired. BioSpectrum is a rapidly growing distributor of surgical solutions within urology, gynaecology and general surgery in the UK market. The company has annual sales of approximately GBP 6 million and 16 employees. BioSpectrum will be part of the Medtech business area.
- Acquisition date: 11 March 2026
- Net sales: approximately 75 MSEK
- Number of employees: 16
CoaChrom Diagnostica
In April CoaChrom Diagnostica GmbH, Austria, was acquired. CoaChrom is a niche company specialising in advanced coagulation diagnostics. The company has annual sales of approximately SEK 108 million and 10 employees. The company will become part of AddLife’s Business Area Labtech.
- Acquisition date: 22 April 2026
- Net sales: approximately 108 MSEK
- Number of employees: 10
AddLife's sustainability strategy
AddLife’s sustainability report describes the business operations and value chain from a sustainability perspective. The sustainability strategy mirrors our key sustainability issues: our positive contribution to the Life Science sector, the well-being and development of our employees, and our work with supply chain management.
AddLife creates value
AddLife aims to create good earnings and a strong shareholder value through independent subsidiaries, active ownership and acquisitions. AddLife's financial targets contribute to a robust cash flow that facilitates self-financed, long-term and profitable growth.
Four reasons to own shares in AddLife
Attractive growth market
Cash flow finances growth
Clear strategy
Market position
Attractive non-cyclical growth market
AddLife predicts that the medtech market has an average annual growth rate of 5 percent and the diagnostics market 2–3 percent. Many of the niches that AddLife has prioritised are growing even faster. The market is relatively insensitive to cyclical fluctuations and is driven by demographic factors, an ageing population and the increasing prevalence of chronic diseases. The demographic factors, together with technological development, an increased demand for preventive and personalised medicine and an increased focus on time-saving processes, are increasing the demand for AddLife’s products in healthcare, Homecare, diagnostics and research.
Cash flow finances growth
In recent years, the Company’s ambition has been to reduce net debt supported by its own cash flow. In 2025, AddLife has achieved and exceeded this ambition and can therefore going forward allocate the majority of its cash flow to organic and acquisition-driven growth. The Company’s acquisition agenda is based on financing acquisitions through its own cash flows. AddLife strives for profitable organic growth and has a high proportion of recurring sales and long-term contracts that generate stable cash flows. With a focus on working capital and profitability, the Company thereby generates strong and stable cash flows over time that can finance growth.
Clear strategy to create growth
A key element of AddLife's growth strategy is acquisitions, with a focus on small and mid-sized bolt-on acquisitions or standalone acquisitions with attractive margins. The company has extensive experience in acquisitions, with an established process for identifying target companies and executing successful transactions. The goal is for the acquired subsidiaries to continue to develop based on their strengths, with the foundation of a decentralised business model, and with the support of an active owner with extensive experience of the Life Science market. Company-specific targets are set for the independent subsidiaries, which are linked to the Group's financial targets.
Strong market position in Europe
AddLife’s business model is based on AddLife, through its subsidiaries, creating value and building leading market positions in selected market niches in Europe. The Group has a broad geographical presence with operations in 30 countries, where AddLife’s subsidiaries have well-established sales organisations with high technical expertise which, in combination with the differentiated product and service portfolio, create strong long-term customer relationships and the conditions for good business.